Lilly acquires new injectable medicine manufacturing facility from Nexus Pharmaceuticals
Upon completion, this acquisition will expand Lilly's growing U.S. capacity to produce the latest life-changing medicines
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Apr 24
Upon completion, this acquisition will expand Lilly's growing U.S. capacity to produce the latest life-changing medicines
13 Mar 24
The Cell Shuttle is an automated, ultra-high throughput, manufacturing platform designed to address the global patient demand while…
27 Feb 24
The nearly 300,000-square-foot facility will employ 400 full-time staff
21 Feb 24
The CTDMO will now begin the analytical testing and manufacturing of the FDA-approved tumour-derived autologous T cell immunotherapy…
07 Feb 24
AstraZeneca said the investment in the new manufacturing facility in Rockville, Maryland, will advance the discovery and development…
24 Nov 23
The investment is expected to boost the manufacturing site's capability and improve Novo Nordisk's capacity to satisfy future…
24 Nov 23
Bayer’s new production facility is grounded in a new platform technology that encompasses a broad spectrum of chemically…
17 Nov 23
The opening of Lilly's first significant production complex in Germany is aligned with the strategy to produce essential…
13 Nov 23
Both companies aim to expand their collaboration to cover the entire project, including the development, production, and clinical…
13 Nov 23
Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines